Table 2. Number of positive NVT, PCV7, the extra 6 serotypes in PCV13 and All (including non-typeable) carriage isolates in 2012/13 and the overall carriage rate for 2001/02, 2008/09, 2012/13 and 2015/16.
The proportion for 2001/02 was calculated accounting for multiple testing of the participants.
| NVT (95% CI)1 | PCV7 (95% CI) | Extra 6 PCV13 serotypes (95% CI) | ALL (95% CI) | ||
|---|---|---|---|---|---|
| <5 years | Participants 15/16 (n = 293) | 150 | 0 | 3 | 152 |
| Proportion 15/16 | 51.1% (45.3–57.0) | 0.0% (0.0–1.3) | 1.0% (0.2–3.0) | 51.9% (46.0–57.7) | |
| Proportion 12/13 | 46.9% (41.1–53.5) | 0.4% (0.0–2.0) | 0.4% (0.0–2.0) | 47.7% (41.8–53.5) | |
| Proportion 08/09 | 37.0% (30.5–44.0) | 4.2% (2.1–8.0) | 9.9%(6.4–14.9) | 51.0% (44.0–58.0) | |
| Proportion 01/02 | 8.5% (6.4–11.1) | 31.9% (28.1–36.1) | 8.0% (6.0–10.6) | 48.4% (44.1–52.7) | |
| 5–20 years | Participants 15/16 (n = 73) | 18 | 0 | 2 | 20 |
| Proportion 15/16 | 24.7% (15.3–36.1) | 0.0% (0.0–4.9) | 2.7% (0.3–9.5) | 27.4% (17.6–39.1) | |
| Proportion 12/13 | 19.6% (13.3–28.0) | 0.9% (0.0–4.9) | 1.8% (0.5–6.3) | 22.3% (15.6–30.9) | |
| Proportion 08/09 | 22.8% (13.8–35.2) | 0.0% (0.0–6.3) | 5.3% (1.8–14.4) | 28.1% (18.1–40.8) | |
| Proportion 01/02 | 8.5% (5.6–12.8) | 10.0% (7.5–13.4) | 2.0% (1.0–4.1) | 21.1% (16.5–26.5) | |
| >20 years | Participants 15/16 (n = 284) | 8 | 0 | 0 | 8 |
| Proportion 15/16 | 2.8% (1.2–5.4) | 0.0% (0.0–1.3) | 0.0% (0.0–1.3) | 2.8% (1.2–5.5) | |
| Proportion 12/13 | 3.1% (1.6–5.7) | 0.0% (0.0–1.3) | 0.3% (0.0–1.9) | 3.4% (1.9–6.1) | |
| Proportion 08/09 | 6.0% (3.1–11.4) | 2.3% (0.8–6.4) | 1.5% (0.4–5.3) | 9.8% (5.8–16) | |
| Proportion 01/02 | 1.9% (1.3–2.9) | 4.0% (3.0–5.4) | 1.6% (1.0–2.5) | 7.6% (6.1–9.4) | |
| All | Participants 15/16 (n = 650) | 176 | 0 | 5 | 180 |
| Proportion 15/16 | 27.0% (23.7–30.7) | 0.0% (0.0–0.6) | 0.7% (0.3–1.8) | 27.7% (24.3–31.3) | |
| Proportion 12/13 | 23.6% (20.5–26.9) | 0.3% (0.1–1.1) | 0.6% (0.2–1.5) | 24.5% (21.4–27.8) | |
| Proportion 08/09 | 24.1% (20.1–28.6) | 2.9% (1.6–5.1) | 6.3% (4.3–9.2) | 33.2% (28.7–38.1) | |
| Proportion 01/02 | 5.2% (4.2–6.5) | 15.2% (13.2–17.4) | 4.1% (3.2–5.2) | 24.4% (21.9–27.1) |
1 6C and non-typeable pneumococci are included in the non-vaccine types. Multiple carriage was detected in 5 individuals. These had 10A/21, 22F/Non-typeable, 23B/Non-typeable, 3/23B and 9N/6C. When assessing the proportion of individuals who carried any VT or NVT serotype, multiple carriage episodes in individuals who carried both a VT and NVT serotype are included. For this reason adding up the number of VT and NVT carriers is one more than the total for carrying any serotype. Non-typeable isolates were counted as NVTs for this analysis to be consistent with the 2012/13 analysis.